Compare Expedia Group Inc (EXPE) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Expedia Group Inc trades at $287.88 (market cap $32.97B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.9 (market cap $977.37M). The key difference: Expedia Group Inc is far larger — about 33.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Expedia Group Inc pays a 0.7% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EXPE | MRVI | |
|---|---|---|
Market Cap | $32.97B | $977.37M |
Volume | 1,375,250 | 2,742,564 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $9.00 |
52-Week Low | $188.51 | $2.83 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $31.53B | $1.08B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $273.44, up 1.85% with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $8.83 EPS. Revenue growth accelerated to $14.73B in 2025, while net income reached $1.29B. Analyst consensus shows a $335.06 price target with 47% buy ratings, though recent news highlights competitive threats from AI travel agents.
EXPE presents a compelling investment case with improving profitability and cash flow generation, but faces significant disruption risks from AI-powered booking platforms. The stock's valuation remains reasonable at 17.28 P/E, though competitive pressures could challenge future growth. Investors should weigh strong fundamentals against emerging technological threats in the travel sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
